logo
Share SHARE
FONT-SIZE Plus   Neg

RyMed Tech. Wins Patent Infringement Case Against ICU Medical - Quick Facts

A federal jury has found in favor of RyMed Technologies and against ICU Medical (ICUI) in a closely-watched patent infringement case, and ruled that RyMed's InVision-Plus with Neutral AdvantageTM technology products do not infringe on a patent held by ICU Medical.

Dana Wm. Ryan, President, CEO and Chairman of the Board of RyMed said the unanimous ruling by an eight-person jury means that ICU Medical can no longer make any claim that RyMed's products literally infringe on an in-force ICU Medical patent.

Commention on the jury's decision, Ryan continued, " It reinforces our ability to continue providing all of RyMed's innovative technology to the market. In addition to providing a significant boost to our future business prospects, it also affirms our ongoing efforts to bring clinicians and patients the very best in IV catheter safety technology."

The jury decision was announced Wednesday, May 9th in a case heard before Judge Leonard P. Stark, in the United States District Court for the District of Delaware.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Kik Interactive Inc., the parent of chat app Kik, said it will launch a new cryptocurrency or token called Kin for use in everyday digital services, such as chat, social media and payments. Kik said it has decided to propose a new ecosystem of digital services that will be truly open and decentralized, and will start with a new cryptocurrency. Several companies have pulled advertisements from Sean Hannity's Fox News show after he continued to promote a conspiracy theory about Democratic National Committee staffer Seth Rich's death. Hannity has come under fire for spreading a conspiracy theory linking Rich's killing to Wikileaks. Best Buy Co., Inc. reported lower profit in its first quarter on the absence of last year's CRT settlement proceeds. However, earnings per share topped market estimates significantly with higher comparable sales. Looking ahead, for the second quarter, the company projects higher comparable sales, and also lifted fiscal 2018 forecast for higher growth.In pre-market, shares were gaining 11.9 percent
comments powered by Disqus
Follow RTT